Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi A. Rodon, Rodrigo Dienstmann, Violeta Serra et al. · Nature Reviews Clinical Oncology · 2013
Cited by 766 works. doi:10.1038/nrclinonc.2013.10
Authors
References
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Integrated genomic analyses of ovarian carcinoma
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
- Comprehensive molecular characterization of human colon and rectal cancer
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
- AKT/PKB Signaling: Navigating Downstream
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity